Our study only suggested that immunochemotherapy was less effective in patients with liver metastasis, and we believe that this is not unique for EGFR-TKI-resistant NSCLC population as liver metastasis has been widely confirmed as an independent factor of treatment resistance and poor prognosis of lung cancer. This evidence concerns the gene EGFR and non-small cell lung carcinoma.